Study at a glance
Why does a vitamin D-processing gene respond differently across tissues?
This study examined why a vitamin D-processing gene responds differently in the kidneys and other tissues. The gene, Cyp24a1, makes an enzyme that helps break down vitamin D compounds. Researchers removed two DNA control regions in mice and tested hormone responses. Human kidney tissue was examined separately to look for related control features.
What happened after the first DNA change?
Removing the region called DS1 greatly reduced the gene’s usual kidney activity and disrupted responses to parathyroid hormone and FGF23. Active vitamin D could still increase activity. The increase was about 740 times the starting value in altered mice, compared with 46 times in the comparison mice. The larger ratio came from a much lower starting point; it did not mean a greater final activity level.
Did changes to vitamin D controls also change blood minerals and bone density?
The gene involved in vitamin D activation also became less active. The pattern of vitamin D compounds changed, but active vitamin D in the blood, calcium, phosphate and bone density stayed broadly similar. Other controls appeared to make up for these changes. Removing the second region, DS2, reduced responses to active vitamin D outside the kidneys without stopping them. Several DNA regions could support the response.
Do these changes in mice show the same vitamin D controls in people?
The DNA sections were removed in mice, so their measured effects cannot be transferred directly to people. Human tissue showed related but more complex arrangements. Apparently normal mineral levels did not mean that the underlying controls were normal. The study also did not show that every tissue outside the kidneys uses the same control pattern.
Read the full article below ↓Meyer and colleagues asked why Cyp24a1, the gene encoding a major vitamin D catabolic enzyme, responds to a complex endocrine programme in kidney but is regulated differently in non-renal tissues. Their experiments show that the answer lies partly in tissue-specific chromatin architecture: kidney uses a pCREB-rich downstream regulatory region for normal basal expression and PTH/FGF23 control, while calcitriol/VDR responsiveness is distributed across several regulatory elements and is more broadly shared across tissues.
What did the researchers study?
The study combined ChIP-seq, enhancer-associated histone mapping, CRISPR/Cas9 genomic deletions, hormonal challenge experiments, renal and non-renal RNA measurements, serum vitamin D metabolite profiling and human kidney chromatin analysis.
Two downstream regions were tested directly. C24-DS1 contained strong kidney-associated pCREB sites and was deleted across approximately 17.5 kb. C24-DS2 contained major VDR sites and was deleted across approximately 2.4 kb. These deletions allowed the researchers to move from “a factor binds here” to the stronger question of whether the region is actually required for gene regulation.
What happened when the kidney-selective DS1 region was deleted?
Basal renal Cyp24a1 expression fell markedly. The mutant kidney also lost normal regulation of Cyp24a1 by PTH and FGF23, establishing that the DS1 region is a major component of the kidney-specific endocrine response.
Cyp27b1 was secondarily suppressed, which is important because it shows that activation and catabolism are coupled. Disturbing Cyp24a1 regulation changes the endocrine environment experienced by the activating enzyme rather than producing an isolated gene-expression defect.
Despite the strong molecular effect, the mice had no striking gross phenotype under the studied conditions. Size, weight, bone mineral density, serum calcium and phosphate were broadly preserved, although PTH was modestly lower and FGF23 somewhat higher. This suggests substantial physiological compensation.
Why is the 46-fold versus 740-fold result important?
Calcitriol could still induce renal Cyp24a1 after DS1 deletion. Wild-type expression rose roughly 46-fold above baseline, while the mutant showed an approximately 740-fold increase.
The 740-fold value is easy to misread. The mutant started from an abnormally low baseline because DS1 deletion had collapsed basal Cyp24a1 expression. Its large fold change therefore does not mean that the mutant reached a vastly greater absolute expression level; the induced response was described as somewhat compromised. The result shows that VDR-dependent induction survives while the kidney-specific basal/PTH/FGF23 module is lost.
What did the metabolite measurements show?
The metabolic phenotype was selective rather than a simple rise in calcitriol. Serum 25(OH)D3 increased from about 14.8 to 51.0 ng/ml, while 24,25(OH)2D3 increased from about 7.8 to 26.5 ng/ml, leaving their ratio close to 2 in both groups.
The C23-associated pathway changed much more strongly. 25(OH)D3-26,23-lactone fell from about 3.1 to 1.1 ng/ml and the 25(OH)D3-to-lactone ratio rose from roughly 4.9 to 47.3. Circulating calcitriol itself was similar at about 24.6 versus 26.8 pg/ml. These values show how regulatory changes can redistribute vitamin D metabolites without producing a simple “more active hormone” pattern.
What did the DS2 deletion reveal?
Deleting the VDR-rich DS2 region reduced calcitriol responsiveness in non-renal target cells but did not abolish it, and renal induction also persisted. The most useful conclusion is redundancy: Cyp24a1 is regulated through several VDR-responsive elements rather than one universal enhancer.
That helps explain tissue differences. Kidney combines specialised pCREB-associated endocrine control with VDR feedback, whereas non-renal tissues can rely more heavily on distributed VDR-responsive elements and other local regulatory inputs.
What are the main limitations?
The causal enhancer deletions were performed in mice. Human kidney chromatin showed broadly related VDR, pCREB and enhancer-associated regions, but the human organisation was more overlapping and complex. The mouse deletion effect should therefore not be translated directly into a quantitative human prediction.
The study also does not show that every non-renal tissue behaves identically. “Non-renal” covers many cell types with different signalling environments. The central finding is tissue dependence, not a single alternative programme that applies everywhere outside kidney.
Why does this matter for vitamin D physiology?
The study shows that the same CYP24A1 enzyme can participate in different physiological jobs depending on how its gene is regulated. The broader Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1) overview places this reciprocal enzyme control in context. In kidney, CYP24A1 is part of reciprocal endocrine control with CYP27B1. In non-renal tissues, local VDR-driven feedback can dominate. Gene presence therefore does not tell you, by itself, which hormones control the enzyme or whether the tissue contributes mainly to systemic or local vitamin D regulation.
Primary source and further reading
Meyer MB, Lee SM, Carlson AH, Benkusky NA, Kaufmann M, Jones G, Pike JW. A chromatin-based mechanism controls differential regulation of the cytochrome P450 gene Cyp24a1 in renal and non-renal tissues. Journal of Biological Chemistry. 2019;294(39):14467 to 14481. PMID 31439663; PMCID PMC6768633; DOI 10.1074/jbc.RA119.010173.
Read the full Meyer et al. paper. The Full Evidence Review develops the chromatin, deletion and metabolite evidence in greater depth.
Related reading
Parathyroid-Specific Deletion of Klotho Unravels a Novel Calcineurin-Dependent FGF23 Signaling Pathway That Regulates PTH Secretion
Their PTH response to intravenous FGF23 delivery or renal failure did not differ compared to their wild-type littermates despite disrupted FGF23-induced activation of the MAPK/ERK pathway.
Original paper ↗Read more →Genetic association of serum calcium, phosphate, vitamin D, parathyroid hormone, and FGF23 with the risk of aortic stenosis
However, evidence of the causal role of mineral metabolism in CAVS is still lacking.
Original paper ↗Read more →Therapeutic Plasma Exchange and Changes in Calcium, Phosphate, Parathyroid Hormone, and Fibroblast Growth Factor-23
This study examined changes in plasma and effluent levels of total calcium, phosphate, PTH, and FGF-23 in individuals undergoing TPE.
Original paper ↗Read more →A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis
The renal actions of parathyroid hormone (PTH) promote 1,25-vitamin D generation; however, the signaling mechanisms that control PTH-dependent vitamin D activation remain unknown.
Original paper ↗Read more →Effects of Different Dietary Interventions on Calcitriol, Parathyroid Hormone, Calcium, and Phosphorus: Results from the DASH Trial
This secondary analysis of the DASH trial aimed to determine the effect of dietary patterns on blood concentrations of calcitriol, parathyroid hormone (PTH), ionized calcium, and urinary excretion of calcium and phosphorus.
Original paper ↗Read more →Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study
We aimed to describe the effect of the calcium phosphate product (Ca*P) on FGF-23 concentrations in children and young adults without confounding cardiovascular disease.
Original paper ↗Read more →Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients
To date, data simultaneously evaluating these parameters and interwoven relations on renal outcomes are scarce.
Original paper ↗Read more →Association between 25-Hydroxyvitamin D, Parathyroid Hormone, Vitamin D and Calcium Intake, and Bone Density in Healthy Adult Women: A Cross-Sectional Analysis from the D-SOL Study
This cross-sectional analysis aimed to investigate the associations of 25(OH)D and plasma PTH concentrations with bone parameters, and potential confounders, in women living in a high (England) or low (Brazil) latitude country.
Original paper ↗Read more →The age-related changes of dietary phosphate responsiveness in plasma 1,25-dihydroxyvitamin D levels and renal Cyp27b1 and Cyp24a1 gene expression is associated with renal α-Klotho gene expression in mice
We found that 1,25-dihydroxyvitamin D levels in plasma were significantly lower in the high phosphate group than the low phosphate group for 1 and 2 month-old mice, but not 13 month-old mice.
Original paper ↗Read more →Gender specific association of parathyroid hormone and vitamin D with metabolic syndrome in population with preserved renal function
The association of parathyroid hormone (PTH) and vitamin D with Metabolic syndrome (MetS) was evaluated using representative data from the Korean population.
Original paper ↗Read more →Interaction between serum FGF-23 and PTH in renal phosphate excretion, a case-control study in hypoparathyroid patients
Serum calcium, phosphate, alkaline phosphatase,parathyroid hormone, FGF-23, 25(OH)D, 1,25(OH)2D and Fractional excretion of phosphorous were assessed and compared between the two groups, using SPSS software.
Original paper ↗Read more →Association between Parathyroid Hormone, 25 (OH) Vitamin D, and Chronic Kidney Disease: A Population-Based Study
A total of 4080 participants were recruited.
Original paper ↗Read more →Associations of Vitamin D Deficiency, Parathyroid hormone, Calcium, and Phosphorus with Perinatal Adverse Outcomes. A Prospective Cohort Study
We aimed to evaluate the association of vitamin D deficiency during early pregnancy with preterm birth.
Original paper ↗Read more →Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia
Hypercalcemic hyperparathyroidism has been associated with poor outcomes after kidney transplantation (KTx).
Original paper ↗Read more →Is low pre-transplant parathyroid hormone a risk marker for cardiovascular disease in long-term follow-up of renal transplant recipients?
We aimed to study the effect of PTH at the time of transplantation on risk of post-transplant vascular events in renal transplant recipients with and without pre-transplant PTX.
Original paper ↗Read more →Misdiagnosis of chronic kidney disease and parathyroid hormone testing during the past 16 years
Chronic kidney disease (CKD) is a prevalent pathological condition worldwide.
Original paper ↗Read more →Prognosis comparison in chronic kidney disease stages 4 to 5 patients with low parathyroid hormone level due to different causes
This study examines prognostic implications of PTH reduction from different etiologies.
Original paper ↗Read more →Tubular functional capacity and maladaptive parathyroid hormone response in early-stage chronic kidney disease
TFC was evaluated by measuring effective renal plasma flow (mERPF, mL/min/1.73m2) using (131I) Hippurate (131I-H) clearance, while GFR was measured using (99m) Tc-DTPA (mGFR, mL/min/1.73m2).
Original paper ↗Read more →Association of increased renal Cyp24a1 gene expression with low plasma 1,25-dihydroxyvitamin D levels in rats with streptozotocin-induced diabetes
Here, we investigated the association between Cyp24a1, a vitamin D catabolic enzyme, and abnormalities in vitamin D metabolism in streptozotocin-induced diabetes rats, an animal model of type 1 diabetes.
Original paper ↗Read more →Renal Dnase1 expression is regulated by FGF23 but loss of Dnase1 does not alter renal phosphate handling
We investigated whether FGF23 suppresses renal Dnase-1 expression to facilitate endocytic retrieval of renal sodium dependent phosphate co-transporters (NaPi-IIa/c) from the brush border membrane by promoting actin polymerization.
Original paper ↗Read more →Renal and Intestinal CYP24A1 Regulation: Study Summary
Study summary of Fuchs and colleagues examining how renal and intestinal CYP24A1 have distinct roles in systemic and local vitamin D clearance.
Read more →Original sources
Read the full Meyer et al. paper
Read the full Meyer et al.
Publication details
Read the full Meyer et al. paper. The Full Evidence Review develops the chromatin, deletion and metabolite evidence in greater depth.